Report Overview

The Global Neurological therapeutics drugs market size is expected to exhibit a CAGR of approximately 5% during the forecast period.

Neurological disorders are an important source of premature mortality and transient or permanent disability in survivors. According to the World Health Organization, Europe accounts for majority of the global burden of neurological disorders contributing to 11.2 % of the disorders. Neurological disorders in the European Union rank third after cardiovascular disorders and cancer accounting for 13.3% of total Disability Adjusted Life Years and 19.5% of total mortalities. Despite the decrease in number of strokes and other infections, there is a considerable increase in the overall burden of neurodegenerative diseases in the country. Neurological disorders are the diseases of the central and peripheral nervous system- the brain, spinal cord, cranial and peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction and muscles. Bacterial, viral, fungal and parasitic infections can cause disturbances to the nervous system. The increased prevalence of neurological complications has warranted a tremendous market growth which provides innumerable opportunities to the Swedish pharmaceutical industry to come up with drug combinations, best suited for the people of the country.



Market Drivers

Neurological Therapeutics drugs market in Sweden is mainly driven by the increase in prevalence of Neurological diseases owing to the rise in the geriatric population. This is directly associated with progressive ageing of the Swedish population and delayed mortality due to development in healthcare services offered to the people.

The older population is highly prone to cognitive impairment and dementia which further drives the market and creates a wider scope for the Sweden Neurological disorder therapeutics market.

A general increase in awareness regarding the neurological diseases and their complications have paved way for improved care which in turn drive the drug market.